Last reviewed · How we verify
Oral Anti Diabetics (OAD)
Oral anti-diabetics are a class of medications that lower blood glucose through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction.
Oral anti-diabetics are a class of medications that lower blood glucose through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Oral Anti Diabetics (OAD) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Oral Anti-Diabetic Agents (multiple classes) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
OADs encompass multiple drug classes (sulfonylureas, metformin, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists, and others) that work through distinct pathways to reduce hyperglycemia. Sanofi manufactures several OAD products across these categories, each targeting different aspects of glucose homeostasis in type 2 diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbances
- Weight gain
- Lactic acidosis (metformin-associated)
Key clinical trials
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
- A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus (PHASE2)
- A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM (PHASE2)
- Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient (PHASE4)
- A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Anti Diabetics (OAD) CI brief — competitive landscape report
- Oral Anti Diabetics (OAD) updates RSS · CI watch RSS
- Sanofi portfolio CI